Successful response to pegylated interferon alpha in a patient with recurrent paraganglioma

Authors:

Abstract
Introduction: Early and accurate identification of recurrences in patients with aggressive paraganglioma (PGL) poses significant challenges. Moreover, the most appropriate therapeutic strategy for recurrent PGL remains to be established. Results: We report the case of 52-year-old man with a history of recurrent, sporadic, left retroperitoneal PGL that relapsed twice (at eight and nine years after the first surgical intervention). At the time of the second recurrence, 2-deoxy-2-[fluorine-18]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) demonstrated a pathologically increased tracer uptake in multiple nodular lesions (10−15 mm in size) located close to the remnant of the left renal pedicle and in the left lombar paravertebral region. Moreover, PET/CT showed a hypermetabolic left supraclavicular lymph node (suggestive of a metastatic disease). Owing to the high surgical risk inherent in a third surgical intervention, the French network for adrenal cancers (COMETE-Cancer) board proposed medical treatment with pegylated interferon alpha (Pegasys; 180 µg per week). After one year of treatment, a 30% decrease in urinary normetanephrine levels was observed. In addition, a marked morpho-metabolic regression of nearly all of the retroperitoneal lesions as well as of the left supraclavicular lymph node was evident. Unfortunately, the patient developed significant signs of drug intolerance, leading to dose tapering and treatment discontinuation. Conclusion: This is the first case of recurrent PGL that showed significant biological and imaging responses to medical treatment with pegylated interferon alpha. Further research on the potential usefulness of this therapeutic approach in patients with relapsing PGL or pheochromocytoma is warranted.

This publication has 10 references indexed in Scilit: